2022 FightMND IMPACT Research Grants

02

03 Acronyms and Definitions

04 Introduction

05 Research Objectives

06 Guidelines

08 Eligibility Criteria08 Eligibility

09 Application Procedure09 NotificationofIntenttoSubmitIMPACTGrantApplication09 Proposals09 CoverSheet(seepage11)09 ProjectPlanandBackground(max.4pages)09 Timeline(max.1page)09 Budget(max.1page)10 References(max.2pages)10 DeclarationofResearchFundingfromOtherSources10 CurriculumVitae(max.2pages)10 LetterofSupportfromtheAdministeringInstitution10 LetterfromCo-Investigators10 CollaboratorsnotNamedasInvestigators10 HowtoSubmit11 2022FightMNDIMPACTGrantCoverSheet

12 Reporting

13 Privacy, Conflict of Interest13 PrivacyandConfidentiality13 ConflictofInterest–ReviewersandGRP13 AcknowledgementofSupport

14 Terms and Conditions14 FightMNDIMPACTGrants

20 Appendix 120 IntellectualPropertyRightsandCommercialActivities

Contents

Administering Institution:Organisationresponsibleforadministrationoftheresearchproject,andthereceiptanddistributionofgrantfunds.AgrantcanonlyhaveoneAdministeringInstitution.

Applicant: Researcherleadingtheresearch–thePrimaryInvestigator(PI),whoisresponsiblefortheoveralldirectionoftheproject,leadingandsupportingco-Investigators(CIs),completionandlodgementoftheapplication,andprogressandreportingontheproject.TheApplicantmustobtainwrittencommitmentfromtheirlaboratoryHeadandHeadsofDepartments/AdministeringInstitutionandmustassumeresponsibilityforundertakingandcompletingtheactivitiesoutlinedintheapplication.Wheretheprojectinvolvesmulti-siteresearch,theApplicantmustobtainwrittencommitmentfromallHeadsofDepartments/AdministeringInstitutionsofcollaborativepartnersandco-InvestigatorsnotwithintheAdministeringOrganisation.

Co-Investigator(s):ResponsibleforcarryingoutsomeaspectsoftheresearchundertheguidanceandleadershipoftheApplicant/PrimaryInvestigator.

Biomarker:Anaturallyoccurringmolecule,gene,orcharacteristicbywhichaparticularpathologicalorphysiologicalprocess,disease,etc.canbeidentified.

Disease model: AdiseasemodelisananimalmodelorcellsdisplayingallorsomeofthepathologicalprocessesthatareobservedinhumanMND.

Gene therapy:Theintroductionofnormalgenesintocellsinplaceofmissingordefectiveonesinordertocorrectgeneticdisorders.

Goods and Services Tax:GoodsandServicesTax(GST)imposedinaccordancewiththeA New Tax System (Goods and Services Tax) Act 1999,andrelatedActsandRegulations.GSTwillbepaidontopofgrantamountswhereappropriate.ThiswillbedeterminedbytheAdministeringInstitution’sGSTstatus.

Motor Neurone Disease (MND):ForthepurposesoftheseIMPACTgrants,thedefinitionofMNDincludesthefollowingprogressiveneurologicaldisordersthatdestroymotorneurons:AmyotrophicLateralSclerosis(ALS);PrimaryLateralSclerosis(PLS);ProgressiveMuscularAtrophy(PMA);ProgressiveBulbarPalsy;andPseudobulbarPalsy.

Translational Research: Researchfacilitatingthetransferortranslationofnewbasicknowledgeofdiseasemechanismsgainedinthelaboratoryintothedevelopmentofnewmethodsforthetreatmentand/orpreventionofMNDinhumans.

Withinthisscope,researchprojectsmayinclude:

•thepreclinicaldevelopmentofnewtreatmentsandinterventionsforMND;or

•testingtheeffectivenessoftreatmentsforMND.

Acronyms and Definitions

03

FightMND call for proposalsGrantapplicationsfornovel,innovativeprojectsthattackleoneormorekeyissuescontributingtothelackofeffectivetreatmentsforMND.

APPLICATIONS OPEN: 01 November 2021

NOTIFICATION OF INTENT TO SUBMIT DUE: 01 March 2022 at 18:00 AEDT

APPLICATIONS DUE: 01 April 2022 at 18:00 AEDT

RECIPIENTS NOTIFIED:July 2022

FightMNDispleasedtoannounceacallforIMPACT(IMProvingandACceleratingTranslation)GrantapplicationstosupportprojectsfocusedononeormoreofthefollowingkeyissuescontributingtothelackoftranslationofeffectivetreatmentsthroughtoclinicaltrialforMND:

I.Diseaseheterogeneity;

II.Alackofrelevantpreclinicalmodels;

III.Alackofreliablediseasebiomarkers;

IV.Thechallengeofdrugdeliveryintothebrainandspinalcord;

V.Alackofeffectivetargetedgenetherapies;and

VI.Theuntappedpotentialofstemcelltherapy.IMPACTGrantssupport2-yearprojectsuptothevalueof$250,000AUD.Proposalsforbothdiscoveryandtranslationalstageresearchwillbeconsidered.

Supportwillnotnormallyexceed2yearsandapplicantsshouldsubmitproposalsthatarefocusedandcompatiblewitha2-yeartimeframe.Thecontinuationoffundingwithinthisperiodwillbesubjecttoperiodicprojectreviewafterthesubmissionofsatisfactoryprogressreports,whicharerequiredatsix-monthlyintervals.

Reporting is an important requirement of IMPACT Grants (see Terms and Conditions 1.1 and 15). Please consider this when planning your experiments and project timelines.

FightMND only supports work carried out in bona fide Research Institutions.

Introduction

04

DespitethefirstdescriptionofMNDover150yearsago,itremainsaterminaldiagnosiswithnoeffectivetreatmentsorcure.Therehasbeenremarkableresearchprogressinthelast25yearsingeneticdiscoveries,developmentofanimalmodelsandinsightsintodiseasemechanismscontributingtoMND.Yet,thesefindingshavefailedtotranslateintosignificantdiseasemodifyingtherapiesoracure.Over60randomisedcontrolledtrialsofproposeddiseasemodifyingdrugs,largelybasedonanimalstudies,havefailedtoshowpositiveresultsinMND(Mitsumotoetal.2014)atanenormouscosttopatients,theirfamilies,thehealthcaresystemanddrugcompanies.

FightMND IMPACT Grants seek to support projects focused on overcoming one or more of the key challenges hindering the translation of promising discoveries into effective therapeutics, with the goal of improving the likelihood of positive clinical trial outcomes.

Priorityareasforinvestigationare:

I.Disease heterogeneity–tomoreaccuratelydefinesubgroupsofMNDpatientstogenerateaprecisionmedicineapproachtoimproverecruitmentintoclinicaltrials;

II.Disease models–thedevelopmentofnovelorimprovedanimalandhumanmodelsofMND,particularlysporadicMND,withthegoalofimprovingthepredictivepowerofpreclinicalmodelsindiscoveringmeaningfuldiseasemodifyingtherapies;

III.Disease biomarkers–thedevelopmentandvalidationofsensitiveandreliablecandidatebiomarkersforMNDdiagnosis,prognosis,diseaseprogressionanddrugefficacy;

IV.Drug delivery–toimproveBloodBrainBarrierpermeabilityofneworexistingdrugsforthetreatmentofMND;

V.Gene therapy–toimprovethetargetingoftreatmentstowardstheunderlyinggeneticsofMNDtoaddressprimarytriggersandcausesofthediseaseandreducetheineffectivetargetingofdownstreamandsecondarypathology;and

VI.Regenerative medicine–thedevelopmentorvalidationofstemcelltransplantationtechniquesthatexplorethepotentialofstemcelltherapyforMND.

Research Objectives

05

IMPACTprojectsmustdemonstratehowdevelopmentsinoneofthesekeyareaswillresultinimprovedoracceleratedtranslationandleadtomoresuccessfulclinicaltrialoutcomesforMNDpatients.

Thescopeforthesetranslationalresearchgrantsisasoutlinedbelow:

•Whererelevant,alldiseasemodelprojectsshouldutiliseacceptedmodelsofMNDanddetailwhythesemodelsarethemostrelevantfortheproposal.

• Disease Heterogeneity – proposalscaninclude,butarenotlimitedto,assessmentofpatientclinical,geneticandmoleculardatatoinspiretailoredtherapies.

• Disease Biomarker – proposalsshouldfocusonfurtherdevelopmentofbiomarkerspreviouslyidentifiedinsamplesfromwell-characterisedhumansubjects,supportedbyareasonablebodyofpreliminarydata.Biomarkersshouldhavearationalbiologicalconnectiontothediseaseprocesses.Typesofbiomarkerscaninclude:

o Companion Biomarkers–Biomarkersthatcanassesstargetengagementanddiseasemodificationofspecificclinical-stagetherapeutics;

o Neuroimaging–Positronemissiontomography(PET)ligandsfortargetengagementandpharmacodynamicmeasurementsofnovelandrepurposedtherapeutics,andnovelmagneticresonanceimaging(MRI)methodstomeasurestructural,bloodflow,andwhite/greymatterchangesinthebrain;

o CSF and blood-based biomarkers –MultiplexELISAandmassspectrometryofparticulartarget(s)ortranscriptomic,proteomic,metabolomic,andlipidomicsignatures;

o Functional activity measures–Electroencephalogram(EEG),magnetoencephalography(MEG),transcranialmagneticstimulation(TMS),electromyography(EMG),electricalimpedancemyography(EIM);and

o Other novel approachesthataresupportedbycompellingevidence.

• Disease Models – proposalsshouldbefocusedongeneratingimprovedmodelsystemsthatmoreaccuratelyreflecthumandisease,whichwillenhancethetranslationpotentialoftherapeuticsandleadtomoresuccessfulclinicaltrialoutcomesforMNDpatients.Prioritydiseasemodelareasinclude:

oNovel disease models:

-Developmentandcharacterisationofnewdiseasemodels;

-Improvementstoexistingmodels;

-ModelsthatreplicateoneormoreuniqueaspectsofMNDpathologypreviouslyundescribedinothermodelsystems;and

-Confirmationandvalidationofnewlydiscovereddisease-causinggenes.

oSporadic MND or common pathologymodels:

-ModelsapplicabletosporadicMNDorrelevanttoarangeoffamilialMNDpatientswillbelookeduponfavourably;and

-ModelsthatmimicarangeofMNDpathologies,particularlythosecommontosporadicMND,e.g.oxidativestress,mislocalisationandaggregationofproteins,motorneuronloss,progressiveparalysisandprematuredeathduetoMNDphenotype.

Guidelines

06

oPatient specific models:

-iPSCorinducedneuronalmodelswhichdisplayhallmarkMNDpathology.

oOther novel models supported by significant evidence.

•Researchersshouldclearlypresentthereasoningbehindthetypeofmodelbeingdeveloped,thebenefitsofthemodeloveranyexistingdiseasemodels,andwhererelevant,howevidenceandvalidationofthisneworimprovedmodelwillbegenerated.

• Drug Delivery – proposalsshouldimprovethebioavailabilityofdrugsbyincreasingblood-brain-barrierpermeabilityormethodofdelivery.Proposalscaninclude:

oUsingnovelmechanismsfordrugdelivery;and

oEstablishingahigh-throughputscreeningplatformforbrain-penetratingdrugstoimprovedrugtargetingandbioavailability.

• Gene therapy – proposalsshouldimprovethetargetingoftherapiesagainstestablishedandnewlydiscoveredMNDgenes,and/orbefocusedonnovelgenetictargetsrelevanttomodifyingdiseasemechanisms.Proposalscaninclude:

oImprovementstoexistinggenetherapydesignordelivery;and

oNovelgenetherapydrugsormolecules.

• Regenerative medicine – proposalsshouldfocusonadvancingthepotentialofstemcelltherapyforthetreatmentofMNDbyinvestigatingthe:

oMostsuitablecelltypefortransplantation;

oMosteffectivesourceforgeneratingthesecells;

oMosteffectiverouteofdelivery;and

oTherapeuticmechanismsfollowingtransplantation.

• Applicants should clearly present the impact of the proposal on translation and clinical trial outcomes for MND patients.

07

EligibilityApplicationsareinvitedfromresearch-basedInstitutionsinAustralia.

Eligiblecandidatesandprojectsforthisawardmustfulfillthefollowingcriteria:

I.Investigatorsatallacademiclevelsareeligibletosubmitapplications;

II.Applicantsareexpectedtopresentnovelproposalsthataredeliverableina2-yeartimeframe;

III.Researchproposals/projectstargetingthetreatmentofsporadicMNDwillbeconsideredfavourably;

IV.Proposalsshouldbehypothesis-drivenwithdefinedaimsandmilestones;

V.Withinthescopeoftheproject,theresearchplanmust demonstratehowtheprojectoutcomeswillimprovethe“bench-to-bedside”potentialforpromisingtherapeutics;

VI.ApplicantsmustdemonstrateoutstandingresearchabilitywithanestablishedordevelopingtrackrecordofresearchimpactandoutputinMNDorrelatedresearch.WhileMNDexperienceisnotessential,applicantsarestronglyencouragedtocollaboratewiththosehavingmoresubstantialexpertiseinMNDresearchand/orMNDmodelsystemswhererelevant;

VII.ResearchproposalsmustbeconductedinanAustralianinstitution.Atthetimeofapplication,thePrimaryInvestigatormaybebasedoverseas.FightMNDwillnotimposeanycriteriaonthenationalityoftheapplicant.Internationalcollaboratorsmaybelistedasco-Investigators;

VIII.Wherepossible,theprojectdemonstratesacollaborativeapproach;

IX.Afulldetailedbudgetfortheproposedprojectwithayear-to-yearbreakdownmustbeincluded.NotethatFightMNDdoesnotfundInstitutionalindirect,overheadoroncosts.Salaryoncostsareacceptableifitemised(e.g.superannuation,payrolltax,workcover);

X.Capitalequipment,depreciation,ormaintenanceofequipmentwillnotbefundedbyFightMNDIMPACTgrants;and

XI.Contributions(ifapplicable)fromotherfundingsourcesshouldalsobeincluded.

Allproposalsshouldbesupportedbyareasonablebodyofpreliminarydataanddemonstratestrongfeasibilityofdeliveryinthe2-yeartimeframe.ThefundedprojectcancommenceonreceiptofasignedGrantAgreementandfirstinvoiceandmust commencewithinthree(3)monthsoftheagreedstartdate(orthegrantshalllapse).

Eligibility Criteria

08

ResearchproposalsaresubmittedtoFightMNDandareindependentlypeer-reviewedpriortoconsiderationbyFightMND’sGrantReviewPanel(GRP).TheGRP’sfundingrecommendationsarethenconsideredbytheBoardofFightMND.KeyfactorsinthedeterminationofawardinganIMPACTgrantwillincludethe:i)researchtrackrecordoftheapplicant;ii)qualityandstrengthoftheresearchproject/plan;andiii)alignmentoftheprojectandapplicanttowardsthecoreaimsandmissionofFightMND.

Notification of Intent to Submit IMPACT Grant Application

PleasenotifyFightMNDofthefollowingdetailrelevanttotheIMPACTgrantapplicationthatwillbesubmitted,by01March2022.

oProposedTitleofproject;

oProposedPrimaryandco-Investigators;

oProposedOthercollaborators

oKeywords

TheseIMPACTgrantdetailsshouldbesubmittedtoFightMND,byemailtoDrDavorStanicatresearchgrants@fightmnd.org.au.

Proposals

Proposalsshouldincludethefollowing:

Cover Sheet (seepage11).

Coversheetsshouldincludethefollowingdetails:

oPrimaryInvestigatorandco-Investigators.

oNameoftheinstitutionwheretheprojectworkwillbeundertaken.

oOthercollaborators(notlistedasInvestigators).

oA 50 word lay summary of the projectsuitableformediareleaseiftheapplicationissuccessful.

oA 250 word lay summaryoftheprojectsuitableforpublicationontheFightMNDwebsiteandnewsletteriftheapplicationissuccessful.

-Providebackgroundinformationnecessaryforreaderswithoutscientificormedicaltrainingtounderstandtherationaleandfeasibilityoftheproposedresearchproject.Itshouldalsoclearlydescribethescientificobjectivetheprojectisdesignedtoachieve.

oStatementonthepotentialIMPACToftheproject.

Project Plan and Background (max.4pages).

Include:

oResearchAimsandHypotheses;

oBackground/SupportingData;

oResearchplan;and

oDescriptionofthepotentialimpactoftheproject.

Timeline (max.1page).

oIncludeadetailedtimelinefortheprojectinGanttchartformat,thatencompassesthedeliveryofresearchaims,proposedexperimentsandoutcomes.

Budget (max.1page).

oProvideanitemisedbudgetwithbreakdownofannualexpenditure.

oBudgetitemscaninclude:

-Salaries(noPrimaryInvestigatororcoInvestigatorsalaries,unlesstheyareanearlyormid-careerresearchersupto7-yearspostPhD).

Salaries,wherejustified,willbesupporteduptoalevelequivalenttothe‘Personnel

Application Procedure

09

SupportPackage4’outlinedbytheNHMRCofAustralia.Seehttps://www.nhmrc.gov.au/funding/manage-your-funding/personnel-and-salary-support-packages

-Salaryoncostsifitemised(e.g.superannuation,payrolltax,workcover);

-Directresearchcosts(reagents,consumables,etc);

-Travelforattendanceandparticipationatacademicconferences(max.$5,000perannum);and

-Coststhatenableopenaccessforpublications(butnootherpublicationcosts).

oBudgetitemscannotinclude:

-Equipment;

-Indirect,overheadoroncostsoftheinstitution.

References (max.2pages).

Declaration of Research Funding from Other Sources

Detailsofresearchfundingobtainedfromothersources(actualorproposed)thatrelatetotheIMPACTGrant’sHypothesis,AimsandResearchPlanmustbedeclared.

Include:

oInvestigator,andTitleofotherApplication;

oFundingSource/OrganisationandApplicationID;

oRoleofInvestigatoronotherApplication;and

oTotalamountrequested.

Curriculum Vitae (max.2pages).

oProvideaCVofmax.2pagesforeachInvestigatornamedontheapplication.

Letter of Support from the Administering Institution

oIncludealetterofsupportfromtheAdministeringInstitutionconfirmingthatappropriateinfrastructure,equipment,andconsumableswillbeavailableandprovidedfortheproposedprojecttocompletion.

Letter from Co-Investigators

oProvidealetter(emailcorrespondence)fromco-Investigatorsconfirmingtheirinvolvementintheprojectproposedintheapplication.

Collaborators not Named as Investigators

oWheretheviabilityofaprojectdependsoncollaboration/involvementwithresearchersorinvestigatorsnotnamedasInvestigatorsontheapplication,theexactroleofthecollaborator(s)shouldbeclearlystatedwithintheProjectPlan,BackgroundandTimelinesectionoftheapplication,andaconfirmationletter(email)fromeachcollaboratorindicatingtheirwillingnesstoparticipatemustbeattachedtothefullapplication.

Reporting is an important requirement for IMPACT grants (see Terms and Conditions 1.1 and 15). Please consider this when planning your experiments and project.

How to Submit

Theapplicationdeadlinesaredescribedinthisguideline.

•Allapplicantsareaskedtosubmittheirapplicationselectronically(filesizenottoexceed5MB)asaPDF(minimumsize12font–calibripreferred,minimum1cmpagemargins).

•ApplicationsaretobesubmittedasasinglePDFdocumentandforwardedtoDrDavorStanicatFightMND,byemailtoresearchgrants@fightmnd.org.aubeforetheclosingdateforapplications.

Please note that applicants are limited to one (1) Primary Investigator and two (2) co-Investigator applications for the IMPACT grant scheme.

10

11

2022 FightMND IMPACT Grant Cover Sheet

1. Project Title

2. Title, name and qualifications of Primary Investigator (PI)

3. Email address of PI

4. Mobile phone no. of PI

5a. Name, institution, % contribution to project and role of PI

5b. Name, institution, % contribution to project and role of co-Investigator

5c. Name, institution, % contribution to project and role of co-Investigator (add rows if more than 2 co-Investigators)

6. Administering Organisation / Sponsoring institution administering the grant

7. Name of research grant administrator for (6)

8. Contact details for (7)

9. Total Budget Estimates for each year Year1$ Year2$ TOTAL-$

10. Details of other collaborators - Name and Institution

11. Key priority area of application

12. Key Words (4 minimum)

13. A 50 word max. lay summary of the project suitable for media release if the application is successful.

14. Summary/Lay description (250 words max. – use separate page if required).

Describeintermsandlanguageapplicable tothegeneralpublic,theoverallaimsand expectedoutcomesofthisproject.

15. Statement on the potential impact of the project (200 words max. – use separate page if required).

12

Reporting

Fundingrecipientswillberequiredtosubmitreportsonaregularbasis.Thereportingscheduleisoutlinedinthefollowingtable.

REPORT REPORTING FREQUENCY DUE

Progressagainstpre-determined 6-monthly Every6monthsfromreceiptmilestonesand/ortargets* offunds

FinancialReports(tobe Annually Every12monthsfromthereceiptincludedinprogressreport)* offunds

FinalReport OnceOnly Atprojectcompletion,orwithin 12weeksafterprojectcompletion.

Adhocreports* AsrequestedbyFightMND Onrequestwithanegotiabletime framenotgreaterthansixweeks

FightMNDResearch Biennially DuringFightMNDResearchSymposiumPresentation Symposium

*Thesereportswillbeusedtoassesswhethertheprojectisproceedingsatisfactorily,whetherfundsarebeingacquittedinaccordancewiththeoriginalapplicationgoals,andtoascertaintheongoingvalueofFightMNDfunding.

Fundingmaybesuspendedifprogressisconsideredunsatisfactory,oriffundshavenotbeenutilisedinaccordancewiththeIMPACTGrantAgreement.

Privacy and ConfidentialityAllinformationcontainedinapplicationsforwardedtoFightMNDwillberegardedasconfidential.DocumentscontainingpersonalinformationwillbehandledandprotectedinaccordancewiththeprovisionsofthePrivacy and Data Protection Act 2014(Vic).Personalinformationwillonlybedisclosedwiththepermissionoftheindividualtowhomitrelates,orwheretheActallows.Applicantsconsenttotheinformationsuppliedaspartoftheirapplicationbeingdisclosedforthepurposesoftheevaluationandadministrationoftheapplicationandgrant.Suchdisclosureincludesbutisnotlimitedtoindependentreviewers/assessors,theFightMNDGrantReviewPanel(GRP),theFightMNDBoard,andrelevantemployeesofFightMNDinvolvedintheresearchgrantprocess.ApplicantsacknowledgethatannouncementoffundedIMPACTGrantapplicationswillinvolveadisseminationofinformationtothepublicabouttheirgeneralnature.

Conflict of Interest – Reviewers and GRPFightMNDrequiresitsindependentreviewersandgrantreviewpaneltoactinanethicalmanner,declareconflictsofinterest,andwithdrawfromconsideringapplicationswheresuchconflictdoesormayexist.

Acknowledgement of SupportSuccessfulapplicantsarerequiredtoacknowledgeFightMNDinanypublications,publicannouncements,media,andscientificmeetingpresentationsordiscussionforumspertainingtoresearchconducted.FightMNDmaterials,logosandimagescanbesuppliedforthispurpose,ifrequired.

13

Privacy, Conflict of Interest

FightMND IMPACT Grants

Terms and Conditions

AllcommunicationconcerningIMPACTgrantapplicationsandadministrationshouldbeaddressedtoDrDavorStanicatFightMND,byemailtoresearchgrants@fightmnd.org.au.

1. Funding Arrangements

1.1.FightMNDIMPACTresearchgrantsaretime-limitedandapplicantsshouldensurethatproperconsiderationisgiventothisintheproposal.Whentheprojectisapprovedinprinciple,theinitialsumawardedbyFightMNDwillbeforthefirstsix(6)monthsonly.Approvaloffundingforsubsequentinvoicesatsix(6)monthlyintervalswillbesubjecttoavailabilityoffundsandthereceipt,fromthegrantee,ofsatisfactoryprojectprogressandfinancialreports.MembersoftheFightMNDteamandBoardwillreviewprogressreportstodecideoutcomes.

1.2.Iftheapplicantunder-spendsinanyyear,FightMNDcan,atitsdiscretion,giveapprovalforthebalancetobecarriedintothefollowingyear.ExpenditurebeyondtheenddatewillonlybepermittedifauthorisedbyFightMNDinadvance.RequestsmustbemadebycontactingFightMNDatleasteightweekspriortotheoriginalcompletiondate,byemailtoDrDavorStanicatresearchgrants@fightmnd.org.au.

1.3.ThevalueoftheIMPACTgrantisuptoatotalof$250,000AUDforprojectperformanceoftwo(2)years.

1.4.FightMNDwillnotmeetindirectoroverheadcostsoron-costsoftheAdministeringInstitution,suchas:generaltravel,financeservices,stafffacilities,staffdevelopment,publicrelations,institutionallibraries,routinesecretarialwork,personnelservices,stationeryorcontributionstogeneraldepartmentalcosts,andpublicationcosts

(exceptforthosenecessarytoenableopenaccessforpublications).

1.5.Conferenceattendance:FightMNDwillallowupto$5,000perannumtowardsthecostofrelevantconferenceattendanceandparticipationbythePrimaryInvestigatortobedrawnfromthetotalsumawarded.Thismaybeusedduringthelifeoftheprojecttowardsthecostsofregistrationfeesandtravel,butnottocoverseparatehotelaccommodationorothersubsistencecosts.Invoices,receiptsorotherevidenceofspendingmustbeprovided.TheInvestigatorsareencouragedtopresenttheirwork.ThePrimaryInvestigatorisexpectedtoattendatleastonerelevantmeetingperyear.

1.6.Paymentofinstalmentsisconditionalonreceiptandapprovalofsatisfactoryprojectprogressandfinancialreports(seeTermsandConditions1.1and15).

1.7.Fundingfromothersources:financialsupportforclearlydefinedaspectsofaprojectfromseparatefundingsourcesispermittedunderFightMNDgrants.Suchsupplementaryfundingmustbedisclosedatthetimeofthegrantapplicationoratthetimesuchfundingisreceived.

2. Equipment

2.1.FightMNDwillnotfundanyequipmentpurchasedaspartofanIMPACTgrant.

3. Ethical Considerations

3.1.ItistheresponsibilityofthePrimaryInvestigatortohaveethicalcommitteeapprovalforallorpartoftheplannedresearch.Thisshouldideallybeinplaceatthetimeofapplyingforfunding.

3.2.Approvalsmustbereceived,andcopiesprovidedtoFightMNDuponrequest,priortotheIMPACTgrantcommencing.

14

Terms and Conditions

4. Personal Direction of the Project

4.1.ItisexpectedthatthePrimaryInvestigatorwillbeactivelyengagedindirectingtheproject.ContinueduseofFightMNDfundsduringaprolongedabsenceofthePrimaryInvestigatorrequireswrittenagreementtocontinuetheresearchunderthedirectionofanotherqualifiedInvestigator,ideallyobtainedpriortotheabsence.TheGranteeoranapprovedrepresentativeoftheAdministeringInstitutionmustapplytoandnotifyFightMNDbyemailtoDrDavorStanicatresearchgrants@fightmnd.org.au,withanexplanationofthesituation,providingdetailsofthearrangementsforconductingtheresearchduringtheirabsence(seeTermsandConditions11.2).

5. Recruitment and Employment of Staff

5.1.FightMNDdoesnotactasanemployerand,therefore,inallcaseswherefinancialsupportisprovidedfortheemploymentofstaff,theAdministeringInstitutionundertakestoissueacontractofemploymentinaccordancewithanyotherrelevantActrelatingtotheconditionsofemployment.

5.2.FightMNDwillnotberesponsibleforclaimsunderstatuteoratcommonlaw,norwilltheyindemnifytheAdministeringInstitutionagainstaclaimforcompensationoragainstanyclaimsforwhichtheInstitutionmaybeliableasanemployerorotherwise.

6. Staff Management Responsibility

TheAdministeringInstitutionmustacceptfullresponsibilityfor:

6.1.Themanagement,monitoringandcontrolforallstaff(permanent,temporaryandstudents)employedorinvolvedinanyresearchfundedbyaFightMNDgrant;

6.2.Themanagement,monitoringandcontrolofallresearchworkfundedasaresultofaFightMNDgrant.

7. Termination of Employment

7.1.IfthetenureoftheappointmentofstaffrecruitedtoworkontheFightMND-supportedprojectcontinuesbeyondthedefinedperiodoftheGrant,theAdministeringInstitutionwillbesolelyresponsibleforallcostsbeyondtheperiodoftheGrant.FightMNDacceptsnoliabilityforcontractsandcostsextendingbeyondthedefinedgrantperiod.

8. Employment Term Contracts

8.1.WheremembersofstaffhavebeenundercontracttotheAdministeringInstitutionpriortotheactivationoftheFightMNDIMPACTgrant,FightMNDwillnotreimbursecostsattributedtoanypriorcommitment.Thisincludesanyredundancypaymentsdueforservicepriortothegrantperiod.

8.2.ThecontractofemploymentofferedmustnotextendbeyondtheterminationoftheIMPACTgrant(unlesstheAdministeringInstitutionwishestoextendthecontractatitsownexpense).

9. Maternity and Other Long-Term Leave

9.1.TheAdministeringInstitutionwillmeetthecostofanylong-termleave,otherthanholiday,andwillensurethatallannualleaveentitlementistakenwithintheIMPACTgrantperiod.Long-termleavemayincludematernity,paternityorlong-termsickleave.

9.2.MaternityorpaternityleaveistheresponsibilityoftheAdministeringInstitutionemployingstaffundertakingaFightMNDproject.LeavewillbeprovidedaccordingtotheAdministeringInstitution’slocaltermsandconditionsofemployment.ThecostsofsuchleavearetheresponsibilityoftheAdministeringInstitutionandarenotprovidedforbyFightMND.

9.3.IfaFightMND-fundedemployeeisduetotakeanyplannedlong-termleave,theIMPACTgrantPrimaryInvestigatorshouldinformFightMNDofthedatesinadvance.ThiswillenablediscussiontodecidewhethertheGrantshouldbesuspendedfortheperiodofabsenceuntilfull-timeemploymentcanberesumed(seeTermsandConditions4and11.2).Ifunplannedlong-termleaveoccurs,theIMPACTgrantPrimaryInvestigatororanapprovedrepresentativeoftheAdministeringInstitutionshouldcontactFightMNDbyemailtoresearchgrants@fightmnd.org.auassoonaspossibletodiscussthesituation.

15

10. Activation of an Awarded IMPACT Grant

10.1.IMPACTgrantsareactivatedonreceiptofasignedGrantAgreementandreceiptofthefirstinvoice.If,foranyreason,thestartdateoftheprojectisdelayedaftertheGrantAgreementhasbeenreturned,FightMNDmustbeinformedatonce,aGrantAgreementDeedofVariationformcompleted,andanewstartdateagreed(seeTermsandConditions11.2).Ifnecessary,arevisedGrantAgreementwillneedtobecompletedandreturned.

10.2.Iftheprojectdoesnotstartwithinthree(3)monthsoftheoriginalagreedstartdate,FightMNDmaywithdrawtheIMPACTgrantoffer.Thegranteeand/orAdministeringInstitutionwillhavetoreapplyforfundinginafuturegrantround,incompetitionwithotherapplicantsatthetime.

10.3.EthicalApproval:FightMNDmustreceiveevidencethatethicalapproval(ifrequired)isinplacepriortotheprojectstarting.Paymentofinvoiceswillbedelayeduntilevidencehasbeenprovided.ItistheresponsibilityofthePrimaryInvestigatortohaveethicalapprovalfortheproposedresearchandthisshouldideallybeinplaceatthetimeofapplyingforfunding.

11. Change of Terms of an Awarded IMPACT Grant

11.1.Reallocationoffundsfromoneexpenseheadingoftheapprovedbudgettoanother,asdetailedintheGrantAgreement,requireswrittenpermissionfromFightMND.

11.2.GranteeswillberequiredtosubmitalettertoFightMNDdetailinganyandallproposedchangestotheproject,andcompleteaGrant Agreement Deed of Variation.Letters/Deeds of Variationmustbesubmittedatleasteightweekspriortothechangestakingplace,andsubmittedforapprovaltoFightMNDbyemailtoDrDavorStanicatresearchgrants@fightmnd.org.au.FightMNDmustbekeptinformedatalltimesofanychangestotheoriginalgrantfundedandtheGrantAgreement.

11.3.AnyrequestformajorchangesinthetermsoftheIMPACTgrant,e.g.foradditionalstafforbudgetitems,mustbemadeintheformofanewandseparategrantapplication,whichwillbeconsideredincompetitionwithallothernewapplications.

12. Changes to Conditions of an Awarded IMPACT Grant

12.1.FightMNDreservestherighttochangetheTermsandConditionsofIMPACTGrantsatanytime.IfthisoccursduringthelifetimeofanIMPACTgrant,therevisedTermsandConditionsmaybeappliedinplaceofthoseissuedatthecommencementoftheIMPACTgrant.

12.2.Successfulapplicantswillbegivenatleast8weeks’noticeofanychangetoconditionsofthegrant.

13. Early Termination of an Awarded IMPACT Grant

13.1.FightMNDreservestherighttoterminatetheawardedIMPACTgrantatanytime.Circumstanceswhichmightleadtoterminationinclude:

•AnybreachintheTermsandConditionsunderwhichtheawardwasmade;

•Iftheprojecthasnotstartedwithinthreemonthsoftheagreedstartdate;

•Theworkisdivergingmarkedlyfromtheoriginalapprovedproject.TheIMPACTGrantPrimaryInvestigatororanapprovedrepresentativeoftheAdministeringInstitutionmustinformFightMNDimmediatelywhentheyareawareofachangeofdirection(seeTermsandConditions11.2).Theremay,however,becircumstancesinwhichthechangeisacceptableonscientificgrounds;

•Failuretosubmitadequateprogressreports,orseriousandunresolvableproblemsidentifiedbyasitevisit;and/or

•WorkhasceasedontheGrant,ortheInvestigatorhasceasedtobeactivelyinvolvedintheproject.FightMNDmustbeinformedimmediatelyifthissituationarises(seeTermsandConditions11.2).

FightMNDwillendeavourtogive60days’priornoticebeforeterminationofanawardedIMPACTgrant.

13.2.IfanIMPACTgrantisterminated,FightMNDwillmeetcostsproperlyandnecessarilyincurredundertheGrantAgreementuptotheterminationdate.However,paymentswillnot,inaggregate,exceedtheamountoftheIMPACTGrantremainingtobepaidatthetimeofitstermination.

16

13.3.IntheeventofworkbeingdiscontinuedbytheAdministeringInstitution,writtennotificationmustbesenttoFightMND,togetherwithareportontheworkcarriedouttodate,settingoutreasonsforthetermination.

14. Extension to an Awarded IMPACT Grant

14.1.ItistheresponsibilityofthePrimaryInvestigatortoapplyforfurthersupportbeforetheendoftheIMPACTGrantperiod,ifthisisrequired.Applicationsforanextensionofsupportmaybeconsideredinisolationorasanewapplicationincompetitionwithotherapplicationsatthetimeofapplying(seeTermsandConditions11.2).

14.2.Adequatetime(atleasteightweeks),shouldbeallowedforanapplicationtobeprocessedandFightMNDacceptsnoresponsibilityforanycostsincurredduetothefailureofagranteetomakesuchanapplicationingoodtime.

15. Reports

15.1.ThePrimaryInvestigatorisrequiredtosubmitthefollowingreports:

•Annual progress reports:dueevery12monthsfromtheIMPACTGrantstartdate,asstatedontheexecutedIMPACTGrantAgreement(seeTermsandConditions1.1).AshortsummaryinlanguageintelligibletothelayreadershouldalsobesubmittedforpossibleuseinFightMNDpublicationsandonourwebsite;

•Interim reports:briefsix-monthlyreportsofnomorethanthreepagesonprojectprogress;

•Final report:requiredwithintwelveweeksaftercompletionoftheIMPACTGrantproject.Adetailedfinalreportcoveringthewholeprojectwillbesubstitutedfortheannualreport.Inaddition,asummaryshouldalsobeprovidedinlanguageintelligibletothelayreader.Researchersmustavoidtheuseofjargonandtechnicallanguageandshouldpitchthesummaryatthelevelofasciencefeatureinabroadsheetnewspaper.ThesummarymaybeusedinFightMNDpublications;and

•FightMND Research Symposium:thePrimaryInvestigatorisrequiredtopresentprogressoftheIMPACTprojectannually,andattheFightMNDResearchSymposium.

15.2.InstalmentsfortheGrantwillbepaidonlyafterreceiptofprogressreportsandtheirapprovalbyFightMND.Paymentmaybedelayedifreportsarenotsubmittedontimeand/orifclarificationisrequired.

15.3.FeedbacktopeoplelivingwithMNDand/orCarers.AllgranteesareencouragedtoprovideregularinformationontheirresearchtobecirculatedbyFightMNDforpatientsandcarers.Wherevolunteersareinvolvedinresearch,granteesarerequiredtoprovideregularfeedbacktotheparticipantsandFightMND,inadditiontoannualreportsandpublications.

16. Site Visits and Progress Meetings

16.1.FightMNDreservestherighttovisitthegrantee’slaboratoriesduringtheperiodoftheIMPACTGranttodiscussprojectprogress,andwelcomesinvitationstodoso.

16.2.Granteesmaybeaskedtoattendsix-monthlyprogressmeetingstodiscussprogresswithFightMNDrepresentativesanddonors.Thesemaybearrangedinconjunctionwithsitevisits.

16.3.GranteesmaybeaskedtotakepartinFightMNDcommunicationprojectssuchasvideocontenttohelpfacilitatefeedbacktoFightMND’sdonorsonoutcomesrelatedtotheIMPACTGrant.

17. Publications, Presentations, Acknowledgments and Publicity

17.1.GranteesareexpectedtoseekpublicationoffindingsinrefereedjournalsduringandassoonaspossibleduringandafterconclusionoftheIMPACTGrantproject(subjecttoTermandCondition18).FightMNDandthegranteeand/orAdministeringInstitutionjointlyundertaketonotifyeachotherbeforepublishedreferenceismadetothefindingsoftheproject,andtodiscusstheformofpublicationwhereverpossible.

17.2.Granteesand/ortheAdministeringInstitutionmustinformFightMNDimmediatelywhenresultsfromFightMND-fundedresearchareacceptedforpublicationorpresentation.ThegranteemustprovideFightMNDwithreprints,photocopiesorelectroniccopiesofthefinalversionofanysuchpublications.

17

17.3.Open Access Policy:Granteesaremandatedtomaketheirpeer-reviewedpapers,directlyarisingfromtheIMPACTGrant,availablethroughopenaccess.TheseresearchpapersshouldbeavailablewithinthePubMedCentralrepositoryassoonaspossible,butdefinitelywithinsixmonthsofpublication.Coststoenableopenaccessforpublicationscanbeincludedintheprojectbudget.

17.4.Posters – costs and accessibility:IfFightMND-fundedresearchisacceptedforpresentationasaposter,thecostsofposterproductionmaybeclaimedaspartoftheconsumablesbudget(toamaximumof$250perIMPACTgrant).ThepostermustacknowledgeFightMNDasasourceoffundingandshouldincludeFightMND’slogo.FightMNDshouldbeprovidedwithanelectroniccopyoftheposterforuseonourwebsiteandsocialmedia.

17.5.Toensurethelong-termsustainabilityofincomeforresearchandtoreflectandmaintainourreputationforfundingresearchofthehighestscientificexcellenceandofgreatestrelevancetoMND,allopportunitiestopromoteFightMNDmustbepursued.TheIMPACTgranteeandtheAdministeringInstitutionareobligedtoco-operatewithFightMNDoveranypublicityorfundraisingactivityarisingfromresearchfundedbyFightMND.Whereitisthemainfunderoftheresearch,FightMNDreservestherighttoleadonpublicity.

17.6.Granteesand/ortheAdministeringInstitutionmustnotifytheFightMNDresearchteambyemailtoDrBecSheeanatresearch@fightmnd.org.auandDrDavorStanicatresearchgrants@fightmnd.org.au,andtheMarketingandCommunicationsDirectorAntheaHargreavesatanthea@fightmnd.org.au,atleastfiveworkingdaysinadvanceofanypublicityarisingfromresearchwhollyorco-fundedbyaFightMNDIMPACTGrant.FightMNDmustbegivenatleast24hours’noticeofanymediareleaseinconnectionwiththefundedproject.AnypressreleaseorothermaterialincludingreferencetoFightMND-fundedresearchmustbeapprovedbyourteambeforeitisreleasedtothemedia.

17.7.InanyoralorwrittenreportorposterpresentationrelatingtoFightMND-fundedresearch,thegranteeand/orauthormustacknowledgeFightMND’ssupportanddisplaytheFightMNDlogowherepractical.AllreferencestoFightMND-fundedworkplacedonwebsites,electronicbulletinboardsandsimilarplatformsmuststateclearlythattheworkisfundedby“FightMND”andideallyalinkshouldbeincludedtotheFightMNDwebsite:www.fightmnd.org.au.

17.8.GranteesmustensurethatFightMND’ssupportisacknowledgedinallpublications,presentationsandsimilarcommunications.ItisessentialforIMPACTgranteestoacknowledgethattheirresearchhasbeensupportedwhollyorinpartbyFightMND,eitherinthetextorinafootnote.TheIMPACTGrantreference/IDmustalsobeprovided.

17.9.WhenspeakingpubliclyandtorepresentativesofthemediaaboutFightMND-fundedresearch,granteesandresearchersshouldensuretheymakeitcleartothemediaandothersthattheyshouldbepresentedasa“FightMND-fundedscientist”.ResearchersshouldconsultwithFightMND’sResearchDirector,DrBecSheean,atresearch@fightmnd.org.auandMarketingandCommunicationsDirectorAntheaHargreavesatanthea@fightmnd.org.au,beforespeakingtothemedia.

17.10.Thereisasubtlebutimportantdifferencebetweenspeakingasa“FightMND-fundedscientist”andactingasaspokespersonforFightMND.Representativesofthemediamaynotalwaysbeawareofthisdifference.GranteesandResearcherswhospeaktothemediamustensurethattheirpersonalviewsarenotmisrepresentedasbeingattributabletoFightMND.

18. Patents, Copyright and Other Intellectual Property

18.1.Ifideas,processesorproductsofpotentialcommercialvaluearegeneratedasaresultoftheproject,theGranteeand/orAdministeringInstitutionmustobtainthewrittenconsentofFightMNDbeforetakinganystepstoexploittheresultscommercially.TheGranteeandAdministeringInstitutionacceptsthatFightMNDmayrequireashareoffinancialgaininreturnforitsconsent.ThisrestrictionshallcontinuetobindthepartiesnotwithstandinganyterminationoftheIMPACTgrant.Forfurtherdetail,pleaseseeAppendix1-Intellectualpropertyrightsandcommercialactivities.

19. FightMND Meetings and Events

19.1.GranteesareaskedtomakethemselvesorotherappropriateresearchteammembersavailabletoreportontheIMPACTGrantprojectatFightMNDmeetings,fundraisingeventsandoccasionallyatothertimesbyinvitation.

18

19.2.TheremaybeoccasionswherethegranteeorotherappropriateresearchteammemberswillbeaskedtopresenttheirworkrelatingtotheIMPACTGrantprojectatscientificandorhealthcareprofessionals’meetings.

19.3.WhenspeakingandpresentingatFightMNDevents,granteesorotherappropriateresearchteammembersareexpectedtomakeitclearinthepresentationtheirfundingconnectionwithFightMND.

20. FightMND Case Studies

20.1.GranteesareaskedtomakethemselvesavailableascasestudiesreflectingtheworkofFightMNDforitswide-rangingcommunicationsandfundraisingactivities.

21. Scientific Integrity

21.1.Intherareeventofscientificfraudoccurring,FightMNDwishestomakeitclearthatitistheresponsibilityoftheemployingauthoritytoinvestigateanysuspectedcaseoffraudulentactivity.FightMNDagreestoprovidefundingprovidingtheemployingauthoritycanproduceevidenceofaprocedurefordealingwithscientificfraud.Iffraudshouldbeproven,theIMPACTGrantmustberepaidinfulltoFightMNDforthwith.

22. Indemnity

22.1.FightMNDdoesnotprovidecoverfornegligentornon-negligentharmforparticipantsinFightMND-fundedstudies.TheAdministeringInstitutionshouldensurethatlocalarrangementsareinplaceshouldclaimsarise.

19

Intellectual Property Rights and Commercial ActivitiesAsacharity,FightMNDisobligedtoensurethattheoutcomesofitsfundedresearchareappliedforthepublicbenefit.Insomecircumstances,thisobligationmaybebestachievedthroughtheprotectionofintellectualpropertyresultingfromtheresearchandthefacilitationofcommercialexploitationofthisintellectualproperty.

Theterm‘intellectualproperty’(IP)describesanyworkorinventionthatresultsfromoriginalcreativethought.

IPfallsintodifferentcategories:

•Copyright:protectswritten,dramaticandartisticwork,software,films,soundrecordingsandbroadcasts.

•Patents:protectstechnicalinventions,novelproductsorprocesses.

•Trademarks:distinguishthegoodsandservicesofoneorganisationfromanother.

•Designrights:protectsthevisualappearanceofproducts.

Someoftheseprotectionsneedtoberegistered(trademarks,patents)andsomedonot(copyright,designrights).IftheIPisnotprotected,anotherindividualororganisationmaycopythedesignorcommercialiseandselltheinventionwithoutconsentorpayment.

Therefore,forgrantswhereFightMNDfundingmayleadtothegenerationofintellectualproperty,thefollowingadditionalconditionsshallapply:

1.1.AnyintellectualpropertydevelopedduringthecourseofconductingresearchsupportedbyFightMNDIMPACTGrantsunderthisagreement(ProjectIP)shallbeownedbytheAdministeringInstitution.

1.2.TheAdministeringInstitutionmustcomplywiththeNationalPrinciplesofIntellectualPropertyManagementforPubliclyFundedResearchbyhavinginplacestrategies,policies,andproceduresfortheidentification,protection,management,andexploitationofintellectualproperty,includingthatresultingfromfundingbycharitiessuchasFightMND.http://www.arc.gov.au/national-principles-intellectual-property-management-publicly-funded-research

1.3.TheAdministeringInstitutionshouldensurethatallpersonsinreceiptoffundingfromFightMND,orworkingonfundedactivity(includingemployees,students,visitingstaffandsub-contractors),areemployedorretainedontermsthatvestintheinstitutionallintellectualpropertyarisingfromfundingbyFightMND.

1.4.TheAdministeringInstitution,grantholdersandco-InvestigatorsshouldinformFightMNDofanypre-existingarrangementsofwhichtheyareaware,andwhichcouldleadtoabreachofFightMND-fundedstandardconditions.Theinstitutionshouldtakereasonableendeavourstoensurethatnoconsultancies,thirdpartyrestrictionsorarrangementswhichmightimpactonaFightMND-fundedgrantareenteredintoinrelationtoanyFightMND-fundedpersonoractivitywithoutprioragreementofFightMND.FightMND-fundedinvestigators,orindividualsinvolvedinaFightMND-fundedproject,shouldnotusematerialsorcompounds(otherthanthoseobtainedcommercially),ontermswhichwouldplacerestrictionsonthepublicationoftheresults.Institutionsshouldtakereasonableendeavourstoensurethat“reach-throughclaims”havenotbeengrantedonanyFightMND-fundedIPinfavourofcommercialorganisationsprovidingmaterialsorcompoundstoFightMND-fundedindividualsforresearchpurposes.However,FightMND

20

Appendix 1

recognisesthatcompaniesprovidingmaterialsmayoftenrequireexclusiverightstoanyintellectualpropertyarisingfromuseofthatmaterial,andthatthisrequirementisoftennon-negotiable.Whereintellectualpropertyarisesfromresearchlinkedindirectlytotheuseofmaterialprovidedundersuchagreement,theprovidershouldbeofferedatime-limitedopportunitytotakeoutarevenuegeneratinglicence.

1.5.TheAdministeringInstitutionandtheIMPACTgrantholdersareboundtonotifyFightMNDpromptlyinwritingwhennewProjectIParisesfromtheGrantandtakereasonablestepstoensurethatsuchIPisprotectedandnotpublishedorotherwisedisclosedpubliclypriortoprotection(whilstatthesametimeensuringthatpotentialdelaysinpublicationareminimised).

1.6. TheAdministeringInstitutionshouldseekFightMND’sconsenttocommerciallyexploittheresultsofanyresearchithasfunded.Consentwillnotbeunreasonablywithheld,andFightMNDwillonlyrefuseanAdministeringInstitution’srequestwhereitconsidersthattheproposedcommercialexploitationwouldruncountertoitsinterestsandcharitableobjectives.IntheeventthatFightMNDdoesnotprovidearesponsetotheAdministeringInstitution’srequestwithinthirty(30)businessdays,theinstitutionoritstechnologytransfersubsidiarywillautomaticallyhavetherighttoproceedwithsuchcommercialexploitation.TheAdministeringInstitutionisnotrequiredtoseekFightMND’sconsentinassigningintellectualpropertytoitstechnologytransfercompany.

1.7.Withinthirty(30)businessdaysofreceivingthenotificationfromtheAdministeringInstitution,andpriortotheAdministeringInstitutionapplyingforregistrationofanyProjectIP,FightMNDwilladvisetheAdministeringInstitutioninwritingwhichoneofthefollowingfinancialarrangementswillapplyinrelationtocommercialisationoftheProjectIP:

I.AllofthecostsassociatedwithcommercialisingoftheProjectIP(includingpatentandlegalcosts)willbepaidbytheAdministeringInstitution.OutofanynetproceedsreceivedbytheAdministeringInstitutionfromcommercialisingtheProjectIP(afteralloftheAdministeringInstitution’scostsassociatedwithcommercialisingtheProjectIPhavefirstbeendeducted),theAdministeringInstitutionwillpay10%ofallnetcommercialisationproceedstoFightMNDuntilsuchtimeasFightMNDhasreceivedanamountequaltotheamountoftheIMPACTGrantfundingprovidedunderthisagreementmultipliedbyfive(5).

II.Tenpercent(10%)ofthecostsassociatedwithcommercialisingtheProjectIP(includingpatentandlegalcosts)willbepaidbyFightMNDasandwhenthecostsfalldue,andtheremaining90%ofthecommercialisationcostswillbepaidbytheAdministeringInstitution.OutofanynetproceedsreceivedbytheAdministeringInstitutionfromcommercialisingtheProjectIP(afteralltheAdministeringInstitution’scostsassociatedwithcommercialisingtheProjectIPhavefirstbeendeductedandFightMND’scostshavebeenreimbursed),theAdministeringInstitutionwillpay10%ofallnetcommercialisationproceedstoFightMNDinperpetuity.

III.FightMNDwillnotseekanypaymentfromthenetcommercialisationproceedsarisingfromcommercialisationoftheProjectIP.

1.8.IftheAdministeringInstitutiondoesnotwishtoprotect,manageorexploittheIP,orfailstocomplywiththeagreedstrategy,FightMNDmaydirecttheAdministeringInstitutiontotakestepstoprotecttheIPattheAdministeringInstitution’sexpenseortotransfertheIPtoFightMND.

1.9.IftheAdministeringInstitutionwishestouseanythirdparty(otherthanitsrecognisedtechnologytransfercompany)tocarryoutitsobligationswithrespecttoIP,itmustprovidedetailsto,andobtainpriorwrittenapprovalfrom,FightMND.

21